A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer
Status: | Active, not recruiting |
---|---|
Conditions: | Breast Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - 74 |
Updated: | 10/20/2018 |
Start Date: | June 25, 2010 |
End Date: | February 2022 |
A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
This study is looking at whether Metformin, an agent that is commonly used to treat diabetes,
can decrease or affect the ability of breast cancer cells to grow and whether Metformin will
work with other therapies to keep cancer from recurring. Health Canada has not approved the
sale or use of Metformin to treat breast cancer, although they have approved its use in this
clinical trial. Although Metformin is approved by the FDA for the treatment of diabetes, its
use in breast cancer is considered investigational.
can decrease or affect the ability of breast cancer cells to grow and whether Metformin will
work with other therapies to keep cancer from recurring. Health Canada has not approved the
sale or use of Metformin to treat breast cancer, although they have approved its use in this
clinical trial. Although Metformin is approved by the FDA for the treatment of diabetes, its
use in breast cancer is considered investigational.
OBJECTIVES:
Primary
- To compare invasive disease-free survival of patients with hormone receptor positive
early-stage breast cancer treated with metformin vs placebo in addition to standard
adjuvant therapy.
Secondary
- To compare overall survival of these patients.
- To compare distant disease-free survival of these patients.
- To compare breast cancer-free interval in these patients.
- To compare changes in body mass index in these patients.
- To compare adverse events in these patients.
- To compare other medical endpoints, including a new diagnosis of diabetes mellitus or
cardiovascular hospitalization (including an emergency room visit or overnight stay) or
death (stroke or myocardial infarction), in these patients.
- To compare health-related quality of life measured using the EORTC QLQ-C30 (supplemented
by a trial-specific checklist), the Block Alive Screener, and physical activity items
from the Nurses Health Study Questionnaire II on a subset of these patients.
- To compare embedded correlative science outcomes including plasma insulin and molecular
markers of metformin action in these patients.
- To compare metabolic parameters including metabolic components of the insulin resistance
syndrome as defined by the ATP III criteria in a subset of these patients.
OUTLINE: This is a multicenter study. Patients are stratified according to hormone-receptor
status (estrogen receptor- and/or progesterone receptor- positive vs both receptors
negative), body mass index (≤ 30 vs > 30 kg/m²), HER2 status (positive vs negative), and
prior chemotherapy (any vs none). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive oral metformin hydrochloride twice daily (once daily in weeks
1-4). Treatment continues for up to 5 years in the absence of disease progression or
unacceptable toxicity.
- Arm II: Patients receive oral placebo twice daily (once daily in weeks 1-4). Treatment
continues for up to 5 years in the absence of disease progression or unacceptable
toxicity.
Blood and tumor samples are collected periodically for correlative studies.
Patients may complete quality-of-life, physical activity, and diet questionnaires at baseline
and at 6, 12, 24, 36, 48, and 60 months. (Sub-set of patients).
After completion of study treatment, patients are followed annually.
Primary
- To compare invasive disease-free survival of patients with hormone receptor positive
early-stage breast cancer treated with metformin vs placebo in addition to standard
adjuvant therapy.
Secondary
- To compare overall survival of these patients.
- To compare distant disease-free survival of these patients.
- To compare breast cancer-free interval in these patients.
- To compare changes in body mass index in these patients.
- To compare adverse events in these patients.
- To compare other medical endpoints, including a new diagnosis of diabetes mellitus or
cardiovascular hospitalization (including an emergency room visit or overnight stay) or
death (stroke or myocardial infarction), in these patients.
- To compare health-related quality of life measured using the EORTC QLQ-C30 (supplemented
by a trial-specific checklist), the Block Alive Screener, and physical activity items
from the Nurses Health Study Questionnaire II on a subset of these patients.
- To compare embedded correlative science outcomes including plasma insulin and molecular
markers of metformin action in these patients.
- To compare metabolic parameters including metabolic components of the insulin resistance
syndrome as defined by the ATP III criteria in a subset of these patients.
OUTLINE: This is a multicenter study. Patients are stratified according to hormone-receptor
status (estrogen receptor- and/or progesterone receptor- positive vs both receptors
negative), body mass index (≤ 30 vs > 30 kg/m²), HER2 status (positive vs negative), and
prior chemotherapy (any vs none). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive oral metformin hydrochloride twice daily (once daily in weeks
1-4). Treatment continues for up to 5 years in the absence of disease progression or
unacceptable toxicity.
- Arm II: Patients receive oral placebo twice daily (once daily in weeks 1-4). Treatment
continues for up to 5 years in the absence of disease progression or unacceptable
toxicity.
Blood and tumor samples are collected periodically for correlative studies.
Patients may complete quality-of-life, physical activity, and diet questionnaires at baseline
and at 6, 12, 24, 36, 48, and 60 months. (Sub-set of patients).
After completion of study treatment, patients are followed annually.
Eligibility Criteria:
- Subjects must have histologically confirmed invasive breast cancer and be enrolled in
the trial within 12 months after the first histologic diagnosis of invasive breast
cancer. A core biopsy interpreted as invasive cancer meets this criterion; otherwise,
the date of first histologic diagnosis will be the date of first surgical procedure
that identifies invasive cancer (biopsy, lumpectomy or mastectomy). Neoadjuvant
subjects should have no evidence of clinical T4 disease prior to chemotherapy and
surgery. Bilateral breast carcinoma is allowed provided diagnoses are synchronous -
that is, within 3 months of one another - and at least one of the two breast
carcinomas meet the eligibility criteria and neither violates the eligibility
criteria.
- All subjects (both adjuvant and neo-adjuvant) must have sentinel lymph node biopsy
and/or axillary lymph node dissection.
Sentinel lymph node biopsy alone is allowed in the following instances:
1. sentinel lymph node biopsy is negative: pN0
2. sentinel lymph node biopsy is positive for isolated tumour cells only: pN0 (i+)
3. * clinically node negative, T1-2 tumours with sentinel lymph node biopsy positive in ≤
2 lymph nodes without extra-capsular extension or matted nodes and undergoing breast
conserving surgery and tangential whole breast irradiation (* excludes subjects
treated with neo-adjuvant systemic therapy)
Definitive surgery and/or chemotherapy have been completed at least 4 weeks prior to
randomization. Surgical margins must be clear of invasive carcinoma. If there is
microscopic residual ductal in situ disease present at lumpectomy or total mastectomy
margins, further excision is highly recommended. If further excision is not undertaken, the
subject may still be entered on study, provided that in addition to breast or chest wall
irradiation, a boost to the tumour bed is delivered. In situ lobular disease at the margin
is acceptable.
Adjuvant subjects with the following pT pN combinations are eligible:
- pT1c, pN0 AND negative estrogen and progesterone receptors AND HER2 negative OR
- pT2N0 and at least one of the following tumour characteristics: histologic grade 3,
lymphovascular invasion, negative estrogen and progesterone receptors, HER2 positive,
Oncotype Dx recurrence score ≥ 25 (or if Oncotype Dx recurrence score is not
available, Ki67 > 14%) OR
- Subjects with pT3, pN0 OR
- Subjects with pT1-3, pN1-3
The eligibility of neo-adjuvant subjects is assessed on the basis of cTNM. The same
eligible TNM combinations apply.
- HER2 status must be known. (Positive = 3+ over-expression by IHC in > 30% of invasive
tumour cells OR HER2 gene amplification by FISH/CISH > 6 HER2 gene copies per nucleus,
OR a FISH/CISH ratio: HER2 gene copies to chromosome 17 signals of ≥ 2.2. All other
results will be considered negative).
- Patients must have had a bilateral mammogram within 12 months prior to randomization,
unless the initial surgery was a total mastectomy, in which case only a mammogram of
the remaining breast is required. (Subjects with bilateral total mastectomies and no
mammogram within 12 months prior to randomization must, instead, have a physical
examination of the chest wall to ensure there is no residual or recurrent disease at
the time of randomization. The date of this examination is used in place of the
mammogram date on the eligibility checklist.)
- Investigations, including chest X-ray or CT chest, bone scan (with radiographs of
suspicious areas) and abdominal ultrasound or liver scan or CT abdomen have been
performed between the first histologic diagnosis and the time of randomization.
- Chest X-Ray, 2 view (or Chest CT) is mandatory
- Bone scans (with x-rays of abnormal areas) are required only if there are signs
or symptoms of metastatic disease
- Abdominal imaging is required only if there are signs or symptoms of metastatic
disease
- Hematology investigations (WBC, Granulocytes, Platelets, Hemoglobin) have been
completed within 28 days prior to randomization and results are available.
- Biochemistry investigations have been completed within 28 days prior to randomization
and values are within the parameters required by the protocol.
AST < 1.8 X ULN; ALT < 1.8 X ULN; Alkaline Phosphatase < 2 X ULN; Serum Creatinine < 115
μmol/L (1.3mg/dL) Serum Bilirubin < institution ULN (except for subjects with Gilbert's
Disease who are eligible despite elevated serum bilirubin level)
- ECOG Performance Status of 0,1 or 2 (at baseline evaluation visit within 28 days prior
to randomization).
- Age ≥ 18 and < 75 and life expectancy of at least 5 years (18 years of age was used as
a cut-off due to the lack of data indicating that breast cancer is a health issue in
the < 18 years age group and metformin safety in pediatric patients has not been
confirmed. Age > 80 carries increased risk of lactic acidosis and study intervention
is for 5 years).
- Subjects must be accessible for treatment and follow-up. Investigators must assure
themselves the subjects randomized on this trial will be available for complete
documentation of the treatment, adverse events, and follow-up.
- In accordance with NCIC CTG policy, protocol treatment is to begin within 10 working
days of patient randomization.
- Subject consent must be obtained according to local Institutional and/or University
Human Experimentation Committee requirements. It will be the responsibility of the
local participating investigators to obtain the necessary local clearance, and to
indicate in writing to the NCIC CTG Study Coordinator that such clearance has been
obtained, before the trial can commence in that centre. Because of differing
requirements, a standard consent form for the trial will not be provided but a sample
form is given. A copy of the initial full board REB approval and approved consent form
must be sent to the central office. The patient must sign the consent form prior to
randomization or registration. Please note that the consent form for this study must
contain a statement which gives permission for the NCIC CTG and monitoring agencies to
review patient records (see Section 16 for further details).
For the first 888 eligible English or French-speaking subjects only (sub-set enrollment
completed 2011NOV04):
- Subject is able (i.e. sufficiently fluent) and willing to complete the Quality of Life
(EORTC QLQ C-30 and Trial Specific Checklist) in English or French. The baseline
assessment must already have been completed at the time of enrollment. Inability
(illiteracy in English or French, loss of sight or other equivalent reason) to
complete questionnaires will not make the patient ineligible for the study; however,
ability but unwillingness to complete the questionnaires will make the patient
ineligible. (Once the target number of 888 subjects is achieved, this criterion will
no longer need to be fulfilled.) [See Appendix VI]. Sub-set enrollment completed
2011NOV04.
- English-speaking subjects who have completed the Quality of Life Questionnaire who are
able (i.e. sufficiently fluent) and willing to complete Nurses Health Study II
Physical Activity Questionnaire and Block Alive Screener in English. The baseline
assessment must already have been completed at the time of enrollment. Inability
(illiteracy in English, loss of sight or other equivalent reason) to complete
questionnaires will not make the patient ineligible for the study; however, ability
but unwillingness to complete the questionnaires will make the patient ineligible.
(This component of the study will close at the same time as the Quality Of Life
sub-study.) Closed to new patient enrollment as of 2011NOV04.
Ineligibility Criteria:
- Subjects with a history of other malignancies, except: adequately treated non-melanoma
skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours
curatively treated with no evidence of disease for ≥ 5 years.
- Subjects with locally recurrent or metastatic breast carcinoma. (Subjects with prior
invasive breast cancer at any time are not eligible. Subjects with prior DCIS only in
either breast are eligible provided the DCIS has been curatively treated including
surgery, radiotherapy and/or Tamoxifen).
- Subjects whose axillary node status is unknown.
- Known diabetes (type 1 or 2) or baseline fasting glucose > 7.0 mmol/L (126 mg/dL).
(Sampled and assayed according to local institution's procedures.)
- Known hypersensitivity or intolerance to metformin.
- Any condition associated with increased risk of metformin-associated lactic acidosis
(e.g. congestive heart failure defined as New York Heart Association {NYHA} Class III
or IV functional status [see Appendix IX], history of acidosis of any type; habitual *
Currently taking metformin, sulfonylureas, thiazolidinediones or insulin for any
reason.
- Current or planned pregnancy or lactation in women of child-bearing potential. Men
should not father a child. (An effective method of birth control should be used while
on study treatment which could include abstinence, IUD, condoms or other barrier
methods of birth control because the safety of metformin in pregnancy or in male
fertility has not been established).
- Concurrent or planned participation in randomized trials of weight loss or exercise
interventions or trials targeting insulin, IGF-1 or their receptors, or involving P13K
inhibitors (at the time of randomization)*.
- These interventions would interfere with the primary endpoint. (Also, in general,
double randomizations in breast cancer trials for MA.32 patients are permitted only if
the patient meets all the eligibility criteria for MA.32 and the sponsor of the
previous trial has no objection to the patient also being enrolled in MA.32).
We found this trial at
282
sites
Click here to add this to my saved trials
Johns Hopkins University The Johns Hopkins University opened in 1876, with the inauguration of its...
Click here to add this to my saved trials
Suburban Hospital Suburban Hospital is a community-based, not-for-profit hospital serving Montgomery County and the surrounding...
Click here to add this to my saved trials
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
Click here to add this to my saved trials
Montefiore Medical Center As the academic medical center and University Hospital for Albert Einstein College...
Click here to add this to my saved trials
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
Click here to add this to my saved trials
University of Vermont The University of Vermont combines faculty-student relationships most commonly found in a...
Click here to add this to my saved trials
University of Chicago One of the world's premier academic and research institutions, the University of...
Click here to add this to my saved trials
Wayne State University Founded in 1868, Wayne State University is a nationally recognized metropolitan research...
Click here to add this to my saved trials
Univ of Hawaii Honolulu Community College is an integral part of the University of Hawai?i,...
Click here to add this to my saved trials
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
Click here to add this to my saved trials
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
Click here to add this to my saved trials
Kinston Medical Specialists offers comprehensive medical services for all ages. Whether it’s a case of...
Click here to add this to my saved trials
University of Southern California The University of Southern California is one of the world’s leading...
Click here to add this to my saved trials
North Shore University Hospital North Shore-LIJ Health System includes 16 award-winning hospitals and nearly 400...
Click here to add this to my saved trials
Beth Israel Med Ctr The physicians and staff of Mount Sinai Beth Israel's Heart Institute...
Click here to add this to my saved trials
Mount Sinai Med Ctr Founded in 1852, The Mount Sinai Hospital is a 1,171-bed, tertiary-care...
Click here to add this to my saved trials
University of Pittsburgh The University of Pittsburgh is a state-related research university, founded as the...
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
Portland, Oregon 97239
503 494-8311
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
Click here to add this to my saved trials
Rhode Island Hospital Founded in 1863, Rhode Island Hospital in Providence, RI, is a private,...
Click here to add this to my saved trials
2279 45th Street
Sacramento, California 95817
Sacramento, California 95817
(916) 734-5800
University of California Davis Cancer Center At UC Davis Comprehensive Cancer Center, specialized teams of...
Click here to add this to my saved trials
Avera Cancer Institute Avera, the health ministry of the Benedictine and Presentation Sisters, is a...
Click here to add this to my saved trials
Wenatchee Valley Medical Center Established on July 21, 2013, Confluence Health is an affiliation between...
Click here to add this to my saved trials
Click here to add this to my saved trials
Akron General Medical Center It
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
University of New Mexico Founded in 1889 as New Mexico’s flagship institution, the University of...
Click here to add this to my saved trials
McFarland Clinic, PC It has been over 65 years since the founders of McFarland Clinic...
Click here to add this to my saved trials
Click here to add this to my saved trials
AnMedical Health Cancer Center Cancer is the general term for a group of more than...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Mission Hospitals Mission Hospital, the flagship hospital of Mission Health, has been committed to improving...
Click here to add this to my saved trials
13001 E. 17th Pl.
Aurora, Colorado 80045
Aurora, Colorado 80045
303-724-5000
University of Colorado Cancer Center - Anschutz Cancer Pavilion The University of Colorado Denver |...
Click here to add this to my saved trials
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
Click here to add this to my saved trials
Click here to add this to my saved trials
Mercy Medical Center "Mercy Medical Center" is a hospital located in Baltimore, Maryland. The landmark...
Click here to add this to my saved trials
22 South Greene Street
Baltimore, Maryland 21201
Baltimore, Maryland 21201
410-328-7904
University of Maryland Greenebaum Cancer Center The University of Maryland Marlene and Stewart Greenebaum Cancer...
Click here to add this to my saved trials
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Mountainview Medical Our medical oncologists, hematologist, and oncology advanced practice nurse, along with other dedicated...
Click here to add this to my saved trials
Click here to add this to my saved trials
Mid Dakota Clinic, PC We're your family clinic, with the doctors you know and trust...
Click here to add this to my saved trials
Click here to add this to my saved trials
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
Click here to add this to my saved trials
Albert Einstein College of Medicine The Albert Einstein College of Medicine of Yeshiva University is...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Maimonides Medical Center At 103 years old, Maimonides Medical Center remains a vital and thriving...
Click here to add this to my saved trials
Bryn Mawr Hospital Bryn Mawr Hospital, a nationally recognized community teaching hospital, is conveniently located...
Click here to add this to my saved trials
Click here to add this to my saved trials
Aultman Health Foundation The Aultman Foundation will raise and administer funds in order to support...
Click here to add this to my saved trials
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
Charleston, South Carolina 29425
843-792-1414
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
Click here to add this to my saved trials
Presbyterian Hospital At Novant Health Presbyterian Medical Center, we are welcoming a new era in...
Click here to add this to my saved trials
Click here to add this to my saved trials
Saint Luke's Hospital St. Luke's Hospital, located in Chesterfield, Missouri, is a regional healthcare provider...
Click here to add this to my saved trials
1969 W Ogden Ave
Chicago, Illinois 60612
Chicago, Illinois 60612
(312) 864-6000
John H. Stroger, Jr. Hospital of Cook County The Level 1 Trauma Center is one...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Case Western Reserve Univ Continually ranked among America's best colleges, Case Western Reserve University has...
Click here to add this to my saved trials
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
Click here to add this to my saved trials
MetroHealth Med Ctr The MetroHealth System is one of the largest, most comprehensive health care...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Mercy Hospital Mercy Hospital, located in Coon Rapids, Minnesota, is a 271-bed non-profit hospital that...
Click here to add this to my saved trials
Click here to add this to my saved trials
Geisinger Medical Center Since 1915, Geisinger Medical Center has been known as the region’s resource...
Click here to add this to my saved trials
Decatur Memorial Hospital An American flag bearing only 48 stars waved above Decatur Memorial Hospital...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Fairview Southdale Hospital Fairview Health Services is an award-winning nonprofit health care system based in...
Click here to add this to my saved trials
Click here to add this to my saved trials
Elkhart Clinic, LLC Informed participation in the management of your health care maximizes your Elkhart...
Click here to add this to my saved trials
Michiana Hematology-Oncology The Advanced Center for Cancer Care in Plymouth is part of the Cancer...
Click here to add this to my saved trials
Elmhurst Memorial Hospital When it comes to medical care, you have a lot of options....
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Sanford Clinic North-Fargo Sanford Health is an integrated health system headquartered in the Dakotas and...
Click here to add this to my saved trials
Sanford Medical Center-Fargo Sanford Medical Center Fargo is a major medical center that provides comprehensive,...
Click here to add this to my saved trials
Click here to add this to my saved trials
McLeod Regional Medical Center McLeod Health, a regional presence and predominant healthcare organization, is dedicated...
Click here to add this to my saved trials
Click here to add this to my saved trials
Front Range Cancer Specialists At Front Range Cancer Specialists, we are dedicated to providing quality...
Click here to add this to my saved trials
Poudre Valley Hospital A 270-bed regional medical center offering a wide array of treatments, surgeries,...
Click here to add this to my saved trials
Click here to add this to my saved trials
Unity Hospital Unity Hospital is one of the Twin Cities
Click here to add this to my saved trials
Northeast Georgia Medical Center Northeast Georgia Health System (NGHS) is a not-for-profit community health system...
Click here to add this to my saved trials
Click here to add this to my saved trials
Addison Gilbert Hospital Addison Gilbert Hospital is a full service, 58-bed medical/surgical acute care facility....
Click here to add this to my saved trials